Table 1.
Percentages of cell viability in CT-26 cells after exposure to a variety of nMOF formulations. Drug concentrations for each drug-loaded nMOF treatment are listed at the top of each column.
| Tal (µM) | 4.80E+00 | 2.40E+00 | 1.20E+00 | 6.00E-01 | 3.00E-01 | 1.50E-01 | 7.50E-02 | 3.70E-02 |
| TMZ (µM) | 4.80E+00 | 2.40E+00 | 1.20E+00 | 6.00E-01 | 3.00E-01 | 1.50E-01 | 7.50E-02 | 3.70E-02 |
| TMZ + Tal (µM) | 9.60E+00 | 4.80E+00 | 2.40E+00 | 1.20E+00 | 6.00E-01 | 3.00E-01 | 1.50E-01 | 7.50E-02 |
| TT@HF-BDC Replicate 1 | 76% | 82% | 87% | 87% | 90% | 90% | 92% | 98% |
| TT@HF-BDC Replicate 2 | 69% | 76% | 77% | 81% | 84% | 82% | 89% | 94% |
| TT@HF-BDC-Dex Replicate 1 | 76% | 79% | 78% | 81% | 85% | 85% | 91% | 97% |
| TT@HF-BDC-Dex Replicate 2 | 78% | 78% | 80% | 79% | 81% | 77% | 90% | 94% |
| TT@HF-BDC-Fuco Replicate 1 | 72% | 60% | 64% | 55% | 65% | 76% | 80% | 85% |
| TT@HF-BDC-Fuco Replicate 2 | 51% | 42% | 54% | 46% | 62% | 68% | 73% | 78% |
| TT@HF-BDC + 2 Gy Replicate 1 | 65% | 55% | 79% | 73% | 72% | 75% | 76% | 81% |
| TT@HF-BDC + 2 Gy Replicate 2 | 65% | 51% | 64% | 57% | 64% | 76% | 71% | 69% |
| TT@HF-BDC-Dex + 2 Gy Replicate 1 | 57% | 46% | 65% | 65% | 67% | 67% | 68% | 81% |
| TT@HF-BDC-Dex + 2 Gy Replicate 2 | 43% | 41% | 47% | 51% | 62% | 57% | 70% | 86% |
| TT@HF-BDC-Fuco + 2 Gy Replicate 1 | 44% | 39% | 55% | 48% | 49% | 49% | 49% | 65% |
| TT@HF-BDC-Fuco + 2 Gy Replicate 2 | 34% | 33% | 34% | 38% | 37% | 38% | 37% | 46% |